254 related articles for article (PubMed ID: 21169407)
21. An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer.
Bild AH; Parker JS; Gustafson AM; Acharya CR; Hoadley KA; Anders C; Marcom PK; Carey LA; Potti A; Nevins JR; Perou CM
Breast Cancer Res; 2009; 11(4):R55. PubMed ID: 19638211
[TBL] [Abstract][Full Text] [Related]
22. lnc-PKD2-2-3, identified by long non-coding RNA expression profiling, is associated with pejorative tumor features and poor prognosis, enhances cancer stemness and may serve as cancer stem-cell marker in cholangiocarcinoma.
Qiu G; Ma D; Li F; Sun D; Zeng Z
Int J Oncol; 2019 Jul; 55(1):45-58. PubMed ID: 31059014
[TBL] [Abstract][Full Text] [Related]
23. A network module-based method for identifying cancer prognostic signatures.
Wu G; Stein L
Genome Biol; 2012 Dec; 13(12):R112. PubMed ID: 23228031
[TBL] [Abstract][Full Text] [Related]
24. Monospecific antibody targeting of CDH11 inhibits epithelial-to-mesenchymal transition and represses cancer stem cell-like phenotype by up-regulating miR-335 in metastatic breast cancer, in vitro and in vivo.
Chen JH; Huang WC; Bamodu OA; Chang PM; Chao TY; Huang TH
BMC Cancer; 2019 Jun; 19(1):634. PubMed ID: 31248373
[TBL] [Abstract][Full Text] [Related]
25. A gene-signature progression approach to identifying candidate small-molecule cancer therapeutics with connectivity mapping.
Wen Q; Kim CS; Hamilton PW; Zhang SD
BMC Bioinformatics; 2016 May; 17(1):211. PubMed ID: 27170106
[TBL] [Abstract][Full Text] [Related]
26. Development of an oncogenic dedifferentiation SOX signature with prognostic significance in hepatocellular carcinoma.
Li MM; Tang YQ; Gong YF; Cheng W; Li HL; Kong FE; Zhu WJ; Liu SS; Huang L; Guan XY; Ma NF; Liu M
BMC Cancer; 2019 Aug; 19(1):851. PubMed ID: 31462277
[TBL] [Abstract][Full Text] [Related]
27. Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer.
Coulouarn C; Factor VM; Thorgeirsson SS
Hepatology; 2008 Jun; 47(6):2059-67. PubMed ID: 18506891
[TBL] [Abstract][Full Text] [Related]
28. A qualitative transcriptional signature to reclassify estrogen receptor status of breast cancer patients.
Cai H; Guo W; Zhang S; Li N; Wang X; Liu H; Chen R; Wang S; Guo Z; Li J
Breast Cancer Res Treat; 2018 Jul; 170(2):271-277. PubMed ID: 29572677
[TBL] [Abstract][Full Text] [Related]
29. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells.
Lawson DA; Bhakta NR; Kessenbrock K; Prummel KD; Yu Y; Takai K; Zhou A; Eyob H; Balakrishnan S; Wang CY; Yaswen P; Goga A; Werb Z
Nature; 2015 Oct; 526(7571):131-5. PubMed ID: 26416748
[TBL] [Abstract][Full Text] [Related]
30. Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.
Rennstam K; McMichael N; Berglund P; Honeth G; Hegardt C; Rydén L; Luts L; Bendahl PO; Hedenfalk I
Breast Cancer Res Treat; 2010 Jul; 122(2):315-24. PubMed ID: 19795205
[TBL] [Abstract][Full Text] [Related]
31. Derivation of molecular signatures for breast cancer recurrence prediction using a two-way validation approach.
Sun Y; Urquidi V; Goodison S
Breast Cancer Res Treat; 2010 Feb; 119(3):593-9. PubMed ID: 19291396
[TBL] [Abstract][Full Text] [Related]
32. A Mutant p53-Dependent Embryonic Stem Cell Gene Signature Is Associated with Augmented Tumorigenesis of Stem Cells.
Koifman G; Shetzer Y; Eizenberger S; Solomon H; Rotkopf R; Molchadsky A; Lonetto G; Goldfinger N; Rotter V
Cancer Res; 2018 Oct; 78(20):5833-5847. PubMed ID: 30154152
[TBL] [Abstract][Full Text] [Related]
33. Breast Molecular Profiling and Radiotherapy Considerations.
Mahmoud O; Haffty BG
Adv Exp Med Biol; 2016; 882():95-124. PubMed ID: 26987532
[TBL] [Abstract][Full Text] [Related]
34. Stem cell-ness: a "magic marker" for cancer.
Lahad JP; Mills GB; Coombes KR
J Clin Invest; 2005 Jun; 115(6):1463-7. PubMed ID: 15931383
[TBL] [Abstract][Full Text] [Related]
35. ABCG2 is a potential marker of tumor-initiating cells in breast cancer.
Sicchieri RD; da Silveira WA; Mandarano LR; de Oliveira TM; Carrara HH; Muglia VF; de Andrade JM; Tiezzi DG
Tumour Biol; 2015 Dec; 36(12):9233-43. PubMed ID: 26091795
[TBL] [Abstract][Full Text] [Related]
36. Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma.
Anguiano A; Tuchman SA; Acharya C; Salter K; Gasparetto C; Zhan F; Dhodapkar M; Nevins J; Barlogie B; Shaughnessy JD; Potti A
J Clin Oncol; 2009 Sep; 27(25):4197-203. PubMed ID: 19636021
[TBL] [Abstract][Full Text] [Related]
37. Stemness of the hybrid Epithelial/Mesenchymal State in Breast Cancer and Its Association with Poor Survival.
Grosse-Wilde A; Fouquier d'Hérouël A; McIntosh E; Ertaylan G; Skupin A; Kuestner RE; del Sol A; Walters KA; Huang S
PLoS One; 2015; 10(5):e0126522. PubMed ID: 26020648
[TBL] [Abstract][Full Text] [Related]
38. Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer.
Duhachek-Muggy S; Qi Y; Wise R; Alyahya L; Li H; Hodge J; Zolkiewska A
Mol Cancer; 2017 Feb; 16(1):32. PubMed ID: 28148288
[TBL] [Abstract][Full Text] [Related]
39. Isolation and characterization of CD105+/CD90+ subpopulation in breast cancer MDA-MB-231 cell line.
Wang X; Liu Y; Zhou K; Zhang G; Wang F; Ren J
Int J Clin Exp Pathol; 2015; 8(5):5105-12. PubMed ID: 26191205
[TBL] [Abstract][Full Text] [Related]
40. Identification of miRNA-Based Signature as a Novel Potential Prognostic Biomarker in Patients with Breast Cancer.
Tang J; Ma W; Zeng Q; Tan J; Cao K; Luo L
Dis Markers; 2019; 2019():3815952. PubMed ID: 31976020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
